阿托伐他汀对原发性高血压患者单核细胞趋化蛋白1和高敏C反应蛋白的干预研究  

Effects of atorvastatin on serum MCP-1 and hsCRP in patients with essential hypertension

作　　者：闫永红 张超 徐俊蛟 杨晓秋 

机构地区：[1]上海市嘉定区南翔医院神经内科,上海嘉定201802 [2]上海市嘉定区南翔医院急诊科,上海嘉定201802

出　　处：《临床荟萃》2012年第1期4-6,共3页Clinical Focus

基　　金：上海市嘉定区卫生局基金(KYXM2009-12-7)

摘　　要：目的观察阿托伐他汀对原发性高血压患者血清单核细胞趋化蛋白1(MCP-1)和高敏C反应蛋白(hsCRP)的影响。方法原发性高血压患者108例,随机分为一般治疗组54例和阿托伐他汀治疗组54例,其中一般治疗组仅给予常规控制血压治疗,阿托伐他汀治疗组给予常规控制血压治疗加阿托伐他汀40mg/d,共观察12周。对所有患者分别于治疗前、治疗4周、8周、12周后各采静脉血1次,测定血浆MCP-1、hsCRP和空腹血糖、血脂(总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、甘油三酯);并监测24小时动态血压。结果一般治疗组患者治疗前血清MCP-1(3.56±0.48)μg/L,治疗4、8、12周MCP-1分别为(3.68±0.36)μg/L、(3.56±0.35)μg/L、(3.52±0.33)μg/L;阿托伐他汀治疗组患者治疗前血清MCP-1(3.58±0.52)μg/L,治疗4、8、12周MCP-1分别为(2.76±0.42)μg/L、(1.48±0.39)μg/L、(1.37±0.31)μg/L。一般治疗组患者治疗前hsCRP(6.62±0.55)mg/L,治疗4、8、12周hsCRP分别为(6.72±0.17)mg/L、(6.51±0.16)mg/L、(6.54±0.15)mg/L;阿托伐他汀治疗组患者治疗前hsCRP(6.07±0.94)mg/L,治疗4、8、12周hsCRP分别为(5.20±0.68)mg/L、(4.14±0.68)mg/L、(3.05±0.55)mg/L。阿托伐他汀治疗组血浆MCP-1和hsCRP水平在治疗前与一般治疗组患者差异无统计学意义(P>0.05),在治疗后MCP-1和hsCRP均明显低于一般治疗组(P<0.01),且随着治疗时间的延长,阿托伐他汀治疗组患者血浆MCP-1和hsCRP水平有明显降低趋势(P<0.01)。结论阿托伐他汀具有抑制原发性高血压患者体内炎症反应的作用。Objective To observe the effects of atorvastatin therapy on serum monocyte chemoattractant protein-1（MCP-1） and high sensitivity C-reactive protein（hs CRP） in patients with essential hypertension（EH）.Methods One hundred and eight EH patients were randomly allocated into two groups：common treated group 54 cases and atorvastatin treated group 54 cases.Patients in common treated group got routine treatment and those in atorvastatin treated group got routine treatment and atorvastatin 40 mg daily.All of them were treated for 12 weeks.We compared serum MCP-1 and hsCRP between common treated group and atorvastatin treated group before treatment and after treatment for 4,8,12 weeks.Results Serum MCP-1 of patients in common treated group before treatment was（3.56±0.48） μg/L,and after treatment for 4 weeks and 8 weeks and 12 weeks,it was respectively（3.68±0.36） μg/L,（3.56±0.35） μg/L and（3.52±0.33） μg/L.Serum MCP-1 of patients in atorvastatin treated group before treatment was（3.58±0.52） μg/L,and after treatment for 4 weeks and 8 weeks and 12 weeks,it was respectively（2.76±0.42） μg/L,（1.48±0.39） μg/L and（1.37±0.31） μg/L.The hsCRP in common treated group before treatment was（6.62±0.55） mg/L,and after treatment for 4 weeks,8 weeks and 12 weeks,it was respectively（6.72±0.17） mg/L,（6.51±0.16） mg/L and（6.54±0.15） mg/L.The hsCRP in atorvastatin treated group before treatment was（6.07±0.94） mg/L,and after treatment for 4 weeks,8 weeks and 12 weeks,it was respectively（5.20±0.68） mg/L,（4.14±0.68） mg/L and（3.05±0.55） mg/L.Before treatment,there were no significant difference in serum MCP-1 and hsCRP between two groups（P0.05）,but after treatment,both indexes were significantly lower in atorvastatin treated group than common treated group（P0.01）,and with the treatment prolonging,serum MCP-1 and hsCRP had obvious descending tendencies in atorvastatin treated group（P0.01）.Conclusion Atorvastatin could effectively restrain in

关 键 词：高血压 C反应蛋白质 趋化因子CCL2 阿托伐他汀 

分 类 号：R544.1[医药卫生—心血管疾病]